Unknown

Dataset Information

0

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.


ABSTRACT: BACKGROUND:Several studies have established a correlation between the VEGF-VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (RAM). However, little is known about the immunological impact of anti-angiogenic reagents within the tumor microenvironment in human clinical samples. This study aimed at investigating the effects of RAM on the tumor microenvironmental immune status in human cancers. METHODS:We prospectively enrolled 20 patients with advanced gastric cancer (GC) who received RAM-containing chemotherapy. We obtained paired samples from peripheral blood mononuclear cells (PBMCs) and tumor-infiltrating lymphocytes (TILs) in primary tumors both pre- and post-RAM therapy to assess immune profiles by immunohistochemistry and flow cytometry. RESULTS:Within the tumor microenvironment, both PD-L1 expression and CD8+ T-cell infiltration increased after RAM-containing therapies. In addition, CD45RA-FOXP3highCD4+ cells (effector regulatory T cells [eTreg cells]) and PD-1 expression by CD8+ T cells were significantly reduced in TILs compared with PBMCs after RAM-containing therapies. Patients with partial response and longer progression-free survival had significantly higher pre-treatment eTreg frequencies in TILs than those with progressive disease. In in vitro analysis, VEGFR2 was highly expressed by eTreg cells. Further, VEGFA promoted VEGFR2+ eTreg cell proliferation, and this effect could be inhibited by RAM. CONCLUSIONS:This study suggests that the frequency of eTreg cells in TILs could be a biomarker for stratifying clinical responses to RAM-containing therapies. Further, we propose that RAM may be employed as an immuno-modulator in combination with immune checkpoint blockade.

SUBMITTER: Tada Y 

PROVIDER: S-EPMC6186121 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8<sup>+</sup> T cells in the tumor microenvironment.

Tada Yasuko Y   Togashi Yosuke Y   Kotani Daisuke D   Kuwata Takeshi T   Sato Eichi E   Kawazoe Akihito A   Doi Toshihiko T   Wada Hisashi H   Nishikawa Hiroyoshi H   Shitara Kohei K  

Journal for immunotherapy of cancer 20181011 1


<h4>Background</h4>Several studies have established a correlation between the VEGF-VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (RAM). However, little is known about the immunological impact of anti-angiogenic reagents within the tumor microenvironment in human clinical samples. This study aimed at investigating the effects of RAM on the tumor microenvironmental immune status in human cancers.<h4>Me  ...[more]

Similar Datasets

| S-EPMC3717059 | biostudies-literature
| S-EPMC8409295 | biostudies-literature
| S-EPMC3686869 | biostudies-literature
| S-EPMC8072204 | biostudies-literature
| S-EPMC6794477 | biostudies-literature
| S-EPMC8375143 | biostudies-literature
| S-EPMC4157120 | biostudies-literature
| S-EPMC3354586 | biostudies-literature
| S-EPMC3169715 | biostudies-literature
| S-EPMC8166155 | biostudies-literature